Overview

Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease

Status:
Completed
Trial end date:
2018-12-13
Target enrollment:
Participant gender:
Summary
Evaluate the tolerability, efficacy and safety of VOS versus Restasis® in subjects with mild to moderate Dry Eye Disease (DED).
Phase:
Phase 2
Details
Lead Sponsor:
Aurinia Pharmaceuticals Inc.
Treatments:
Cyclosporine
Cyclosporins
Ophthalmic Solutions
Pharmaceutical Solutions